Document Detail

Genomic Analysis Highlights the Role of the JAK-STAT Signaling in the Anti-proliferative Effects of Dietary Flavonoid-'Ashwagandha' in Prostate Cancer Cells.
MedLine Citation:
PMID:  18955307     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Phytochemicals are dietary phytoestrogens that may play a role in prostate cancer prevention. Forty percent of Americans use complementary and alternative medicines (CAM) for disease prevention and therapy. Ashwagandha (Withania somnifera) contains flavonoids and active ingredients like alkaloids and steroidal lactones which are called 'Withanolides'. We hypothesize that the immunomodulatory and anti-inflammatory properties of Ashwagandha might contribute to its overall effectiveness as an anti-carcinogenic agent. The goal of our study was gain insight into the general biological and molecular functions and immunomodulatory processes that are altered as a result of Ashwagandha treatment in prostate cancer cells, and to identify the key signaling mechanisms that are involved in the regulation of these physiological effects using genomic microarray analysis in conjunction with quantitative real-time PCR and western blot analysis. Ashwagandha treatment significantly downregulated the gene and protein expression of proinflammatory cytokines IL-6, IL-1β, chemokine IL-8, Hsp70 and STAT-2, while a reciprocal upregulation was observed in gene and protein expression of p38 MAPK, PI3K, caspase 6, Cyclin D and c-myc. Furthermore, Ashwagandha treatment significantly modulated the JAK-STAT pathway which regulates both the apoptosis process as well as the MAP kinase signaling. These studies outline several functionally important classes of genes, which are associated with immune response, signal transduction, cell signaling, transcriptional regulation, apoptosis and cell cycle regulation and provide insight into the molecular signaling mechanisms that are modulated by Ashwagandha, thereby highlighting the use of this bioflavanoid as effective chemopreventive agent relevant to prostate cancer progression.
Ravikumar Aalinkeel; Zihua Hu; Bindukumar B Nair; Donald E Sykes; Jessica L Reynolds; Supriya D Mahajan; Stanley A Schwartz
Related Documents :
20978267 - Novel therapeutic agents for b-cell lymphoma: developing rational combinations.
20306477 - Tocotrienols activity in mcf-7 breast cancer cells: involvement of erbeta signal transd...
18524957 - Hedgehog signalling in endocrine development and disease.
24028077 - The globular heads of the c1q receptor regulate apoptosis in human extravillous cytotro...
15165007 - Graves' ophthalmopathy: state of the art and perspectives.
3000367 - Activation by gamma interferon of human macrophage capability to produce toxic oxygen m...
Publication Detail:
Type:  Journal Article     Date:  2008-01-10
Journal Detail:
Title:  Evidence-based complementary and alternative medicine : eCAM     Volume:  7     ISSN:  1741-4288     ISO Abbreviation:  Evid Based Complement Alternat Med     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2011-05-11     Completed Date:  2011-07-14     Revised Date:  2011-07-28    
Medline Journal Info:
Nlm Unique ID:  101215021     Medline TA:  Evid Based Complement Alternat Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  177-87     Citation Subset:  -    
Department of Medicine, Division of Allergy, Immunology, and Rheumatology, Buffalo General Hospital, Kaleida Health System and Center for Computational Research, New York State Center of Excellence in Bioinformatics and Life Sciences and Department of Biostatistics, University at Buffalo, State University of New York (SUNY), New York State Center of Excellence, Buffalo, NY 14203, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pediatric acupuncture: a review of clinical research.
Next Document:  Anti-microbial Activity of Urine after Ingestion of Cranberry: A Pilot Study.